Form 4: Sage Therapeutics Director George Golumbeski Granted Stock Options

Director George Golumbeski received stock options for 12,500 shares of Sage Therapeutics, Inc., vesting in full by June 2025, according to a recent SEC filing.

Summary

• George Golumbeski, a director at Sage Therapeutics, Inc., was granted stock options to purchase 12,500 shares.
• The options were granted on June 10, 2024, with an exercise price of $10.90 per share.
• The options will vest in full upon the earlier of June 10, 2025, or the day immediately prior to the 2025 Annual Meeting of Sage's stockholders, contingent upon continued service as a director.
• Golumbeski also granted a Power of Attorney to Anne Marie Cook, Kimi Iguchi, Brandon Marsh and Stuart Falber to prepare and file SEC forms on his behalf.

Sentiment

Score: 7

Explanation: The document indicates a standard compensation practice (stock options) for a director, suggesting a stable and incentivized leadership structure. This is generally viewed positively.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule incentivizes continued service as a director.

Future Outlook

The stock options will vest based on continued service as a director, aligning the director's interests with the company's long-term performance.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, used to attract and retain talent and align their interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in publicly traded companies, particularly in the biotech and pharmaceutical sectors.
• Companies like Biogen, Vertex Pharmaceuticals, and Amgen also utilize stock options as part of their director compensation programs.
• The vesting schedule and exercise price are typical for such grants, designed to incentivize long-term commitment and performance.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of the shareholders, potentially leading to decisions that benefit the company's long-term value.
• The vesting schedule incentivizes the director to remain engaged and contribute to the company's success.

Key Dates